Bei Jing Shang Bao·2026-01-06 12:09Group 1 - The core point of the article highlights a significant leadership change at Kunming Pharmaceutical Group, with the resignation of Chairman Wu Wendo, President Yan Wei, and Vice President Li Lichun, and the appointment of Yu Xiang and Zhong Jiang from China Resources Sanjiu as new Chairman and President respectively, indicating an escalation of control by China Resources over Kunming Pharmaceutical amid ongoing performance pressures [1][3][4] - The leadership transition occurs less than a year after the last major executive changes, reflecting China Resources Sanjiu's intensified efforts to integrate and manage Kunming Pharmaceutical, which has been facing substantial operational challenges [3][4] - Kunming Pharmaceutical's performance has deteriorated significantly, with revenue and net profit both declining sharply in the first three quarters of 2025, down 18.08% and 39.42% year-on-year respectively, marking the lowest figures in nearly six years [5][6] Group 2 - The company attributes its performance issues to the pains of channel reform, as it shifts from traditional sales methods to a modernized channel system, which has temporarily affected sales efficiency [6] - The new management team, particularly Yu Xiang, is expected to leverage their experience in OTC and health business to reverse the current downward trend in performance and align with the strategic transformation of Kunming Pharmaceutical [6][9] - The broader context includes a trend within China Resources Pharmaceutical, where recent executive changes across various subsidiaries signal a shift from aggressive acquisition strategies to a focus on internal integration and operational efficiency [7][8]